Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems

A wide variety of assessment tools have been proposed for hidradenitis suppurativa (HS) until now, but none of them meets the criteria for an ideal score. Because there is no gold standard scoring system, the choice of the measure instrument depends on the purpose of use and even on the physician’s experience in the subject of HS. The aim of this study was to assess the intrarater and interrater reliability of 6 scoring systems commonly used for grading severity of HS: the Hurley Staging System, the Refined Hurley Staging, the Hidradenitis Suppurativa Severity Score System (IHS4), the Hidradenitis Suppurativa Severity Index (HSSI), the Sartorius Hidradenitis Suppurativa Score and the Hidradenitis Suppurativa Physician’s Global Assessment Scale (HS-PGA). On the scoring day, 9 HS patients underwent a physical examination and disease severity assessment by a group of 16 dermatology residents using all evaluated instruments. Then, intrarater reliability was calculated using intraclass correlation coefficient (ICC), and interrater variability was evaluated using the coefficient of variation (CV). In all 6 scorings the ICCs were >0.75, indicating high intrarater reliability of all presented scales. The study has also demonstrated moderate agreement between raters in most of the evaluated measure instruments. The most reproducible methods, according to CVs, seem to be the Hurley staging, IHS4, and HSSI. None of the 6 evaluated scoring systems showed a significant advantage over the other when comparing ICCs, and all the instruments seem to be very reliable methods. The interrater reliability was usually good, but the most repeatable results between researchers were obtained for the easiest scales, including Hurley scoring, IHS4 and HSSI.

[1]  Ł. Matusiak Profound consequences of hidradenitis suppurativa: a review , 2020, The British journal of dermatology.

[2]  A. Ionescu,et al.  Inter‐rater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa/acne inversa , 2019, The British journal of dermatology.

[3]  A. Gottlieb,et al.  Inter‐rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa , 2019, The British journal of dermatology.

[4]  A. Vossen,et al.  Correlation of the refined Hurley classification for hidradenitis suppurativa with patient‐reported quality of life and objective disease severity assessment , 2019, The British journal of dermatology.

[5]  A. Kimball,et al.  Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  A. Gottlieb,et al.  A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process , 2018, The British journal of dermatology.

[7]  D. Presser,et al.  Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity , 2017, The British journal of dermatology.

[8]  V. Piguet,et al.  Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process , 2016, The British journal of dermatology.

[9]  G. Jemec,et al.  New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes. , 2015, Journal of the American Academy of Dermatology.

[10]  S. Chimenti,et al.  AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa. , 2015, Wounds : a compendium of clinical research and practice.

[11]  C. Zouboulis,et al.  Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation , 2015, Dermatology.

[12]  J. Lapins,et al.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  J. Rhodes,et al.  The surface area of the hand and the palm for estimating percentage of total body surface area: results of a meta‐analysis , 2013, The British journal of dermatology.

[14]  G. Jemec Clinical practice. Hidradenitis suppurativa. , 2012, The New England journal of medicine.

[15]  J. Lapins,et al.  Interobserver variability of clinical scores in hidradenitis suppurativa is low , 2010, The British journal of dermatology.

[16]  J. Szepietowski,et al.  Hidradenitis suppurativa markedly decreases quality of life and professional activity. , 2010, Journal of the American Academy of Dermatology.

[17]  O. Faye,et al.  Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. , 2008, Journal of the American Academy of Dermatology.

[18]  A. Loundou,et al.  Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. , 2007, Journal of the American Academy of Dermatology.

[19]  J. Lapins,et al.  Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa , 2003, The British journal of dermatology.

[20]  G. Jemec,et al.  The prevalence of hidradenitis suppurativa and its potential precursor lesions. , 1996, Journal of the American Academy of Dermatology.

[21]  E. Prens,et al.  Hurley Staging Refined: A Proposal by the Dutch Hidradenitis Suppurativa Expert Group. , 2017, Acta dermato-venereologica.

[22]  A. Alikhan Hidradenitis Suppurativa. , 2016, JAMA dermatology.

[23]  S. Kolenik Dermatologic Surgery Principles and Practice , 1989, The Yale Journal of Biology and Medicine.